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Formulations of cationic liposomes and polymers readily self-assemble by electrostatic interactions with
siRNA to form cationic nanoparticles which achieve efﬁcient transfection and silencing in vitro. However,
the utility of cationic formulations in vivo is limited due to rapid clearance from the circulation, due to
their association with serum proteins, as well as systemic and cellular toxicity. These problems may be
overcome with anionic formulations but they provide challenges of self-assembly and transfection ef-
ﬁciency. We have developed anionic, siRNA nanocomplexes utilizing anionic PEGylated liposomes and
cationic targeting peptides that overcome these problems. Biophysical measurements indicated that at
optimal ratios of components, anionic PEGylated nanocomplexes formed spherical particles and that,
unlike cationic nanocomplexes, were resistant to aggregation in the presence of serum, and achieved
signiﬁcant gene silencing although their non-PEGylated anionic counterparts were less efﬁcient. We have
evaluated the utility of anionic nanoparticles for the treatment of neuronal diseases by administration to
rat brains of siRNA to BACE1, a key enzyme involved in the formation of amyloid plaques. Silencing of
BACE1 was achieved in vivo following a single injection of anionic nanoparticles by convection enhanced
delivery and speciﬁcity of RNA interference veriﬁed by 50 RACE-PCR and Western blot analysis of protein.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
SiRNAs are double-stranded nucleic acids of 20e23 nucleotides
which exploit endogenous enzymatic pathways found ubiquitously
in nature to regulate gene expression by degradation of messenger
RNA leading to gene silencing [1]. SiRNA can be delivered as a
synthetic molecule to silence any speciﬁc gene and thus offer a
wide range of therapeutic opportunities for the treatment of dis-
eases by silencing genes involved in pathogenic pathways [2].
Numerous clinical trials of siRNA therapies are currently in progress
for diseases in the eye, liver and lung as well as cancers [3-5]. Safe
and efﬁcient delivery of siRNA to affected tissues, however, remains
a major technical barrier to the implementation of siRNA therapies
[6].: þ44 2079052810.
a.tagalakis@ich.ucl.ac.uk
r Ltd. This is an open access articleSiRNAs are susceptible to degradation by RNases that are
ubiquitous in vivo and, as they are anionic, hydrophilic molecules,
are unable to cross the cell membrane efﬁciently [3]. Other prob-
lems include overcoming further intracellular barriers such as
endosomal release, and to avoid the non-speciﬁc uptake by the
reticuloendothelial system (RES) by its efﬁcient delivery into target
tissues. Nanocomplex formulations for siRNA delivery are therefore
widely used and most of these are cationic as they enable self-
assembly, cell binding and efﬁcient transfection [4]. However,
cationic formulations may be problematic for some applications
in vivo as they interact with proteins in biological ﬂuids and non-
speciﬁcally with cells and form aggregates, leading to toxicity,
poor biodistribution and immune responses [7,8]. These effects can
be partially mitigated by PEG shielding of the surface charge [7] but
anionic nanoparticle formulations offer another solution to these
problems. Assembly between anionic polymers or lipids and
nucleic acids can be achieved by including cationic bridging agents
in the formulations such as Ca2þ cations [9-11], polymers and PEI
[12,13], electrostatic coating [14] and protamine [15] which haveunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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promising evidence of efﬁcacy and improved toxicity of anionic
siRNA nanoparticles compared to cationic formulations.
We have previously described multifunctional Receptor-
Targeted Nanocomplex (RTN) formulations comprising mixtures
of cationic liposomes (L) and cationic targeting peptides (P) which
self-assemble, electrostatically on mixing with plasmid DNA (D) or
siRNA (R) and achieved efﬁcient in vitro and in vivo gene delivery
[16-21]. RTN formulations comprise a peptide which packages
nucleic acids through a cationic K16 motif and receptor-targeting
ligand for cell binding. Cationic LPR nanocomplexes containing
siRNA were optimized with regard to their transfection efﬁciency
and biophysical properties [19,21]. The optimal liposome compo-
nent of RTNs for siRNA delivery in vitro was the cationic lipid
formulation DOTMA/DOPE, which probably enhances transfection
by destabilizing the endosomal bilayer allowing release of the
siRNA to the cytoplasm before endosomal degradation can occur
[19].
In this study we have developed anionic PEGylated RTNs for
siRNA delivery, consisting of anionic liposome and a sixteen-lysine
peptide with a targeting motif and assessed in vitro for their bio-
physical properties, cytotoxicity and receptor-mediated trans-
fection efﬁciency. We have previously shown that anionic particles
achieved more widespread dispersal in the brains of rats than
cationic nanoparticles when delivered by convection-enhanced
delivery (CED) directly into the corpus callosum or striatum due
to their lower afﬁnity for anionic cell surface glycoproteins [22,23]
and have therefore explored the potential of anionic siRNA nano-
complexes for neurodegenerative diseases. Beta-site amyloid pre-
cursor protein cleaving enzyme 1 (BACE1), which encodes b-
secretase, is expressed in neurons and cleaves the amyloid pre-
cursor protein (APP) to generate amyloid-beta (Ab) peptides. This
protein is over-expressed in the brains of patients with Alzheimer's
disease (AD) and is proposed to lead to the production of amyloid
plaques [24]. Ab peptides play a crucial role in AD pathogenesis, and
aggregates of these peptides initiate a cascade which ultimately
leads to neurodegeneration [25]. BACE1 is therefore a target for the
treatment of AD but efﬁcient delivery modalities are required that
circumvent the blood brain barrier and transfect neurons
throughout the brain. In this study we have optimized anionic
nanocomplexes in vitro and then administered a formulation with
BACE1 siRNA into rat brain by CED and assessed target gene
silencing as a therapeutic option for AD.
2. Materials and methods
2.1. Materials
1,2-dioleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG), 1,2-di-O-octade-
cenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
-N-[methoxy(polyethylene glycol)-2000] (DPPE PEG2000), 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DOPE PEG2000)
and DOTMA/DOPE (1:1 molar ratio) were purchased from Avanti Polar Lipids
(Alabaster, Alabama, USA). The structures of the lipids used are shown in
Supplementary Table S1. Peptide Y (K16GACYGLPHKFCG), Peptide ME27
(K16RVRRGACRGDCLG) and non-targeting peptide ME72 (K16RVRRGACRGECLG)
were synthesized by ChinaPeptides (Shanghai, China), whereas non-targeting
peptide K16 (KKKKKKKKKKKKKKKK) was synthesized by Alta Biosciences (Bir-
mingham, UK). The siRNAs used for in vitro studies were: Silencer GAPDH siRNA,
Silencer Fireﬂy Luciferase (GL2þGL3) and Silencer Negative Control #1 siRNA all
bought from Applied Biosystems (Warrington, UK). The siRNA for BACE1 in vivo
studies was bought form Euroﬁns MWG Operon (Ebersberg, Germany) and the se-
quences were: BACE1 (sense) 5' GCUUUGUGGAGAUGGUGGAdTdT3' and BACE1
(antisense) 5' UCCACCAUCUCCACAAAGCdTdT 3'. Lipofectamine 2000 (L2K) was
purchased from Invitrogen (Paisley, UK).
2.2. Liposome formulation
Lipids were dissolved in chloroform at 10 mg/ml and mixed, followed by pro-
duction of a lipid ﬁlm by slowly evaporating the chloroform. Lipids were rehydratedwith sterile, distilled water whilst constantly being rotated overnight and then
sonicated in a water bath to reduce their size. Anionic liposomes made were:
DOPG:DOPE (LA) at 1:1 molar ratio; DOPG:DOPE:DPPE PEG2000 (LAP1) at a molar
ratio of 47.5:47.5:5 mol%, respectively; DOPG:DOPE:DOPE PEG2000 (LAP2) at a molar
ratio of 47.5:47.5:5 mol%, respectively.
2.3. Nanoparticle formulation
Anionic nanocomplexes were prepared in water at different molar charge ratios
of L to R, with the peptide P to R molar charge ratio constant at 3:1, by two methods.
Method 1 (L:R:P): siRNAwas ﬁrst added to one of the liposomes LA, LAP1 or LAP2 and
incubated for 15 min at room temperature and then the peptide was added with
rapid mixing and incubated at room temperature for a further 20 min; Method 2
(P:R:L): the peptide was added to the siRNA and incubated for 15 min at room
temperature and then liposomewas addedwith rapidmixing and incubated at room
temperature for a further 20 min. For both methods of mixing the weight ratio of
liposome to siRNA was 19:1 for LA and 20:1 for LAP1 and LAP2. Cationic LPR (1:4:1
weight ratio of liposome:peptide:siRNA) formulations weremade by ﬁrst adding the
peptide to the liposome DOTMA/DOPE followed by addition of the siRNAwith rapid
mixing and incubated for 30 min at room temperature to allow for complex for-
mation. The nanocomplexes prepared were termed LPR (liposome DOTMA/DOPE),
PRLA or LRPA (liposome LA), PRLAP1 (liposome LAP1) and PRLAP2 (liposome LAP2).
2.4. In vitro transfections
Neuro-2A cells (ATCC, Teddington, UK) and Neuro-2A-Luc cells stably expressing
luciferase [21] were maintained in Dulbecco's minimal essential medium (DMEM;
Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum, 1% non-essential
amino acids, and 1% sodium pyruvate. The human airway epithelial cells
1HAEo were provided by D. Gruenert, (San Francisco, CA, USA) and were
cultured in Eagle's minimal essential medium (MEM) with (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) modiﬁcation (SigmaeAldrich, Poole, UK) sup-
plemented with 10% foetal calf serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin, and 2 mol/l L-glutamine. All cells were maintained at 37 C in a
humidiﬁed atmosphere in 5% carbon dioxide.
Cells were seeded in 96-well plates at 2  104 per well 24 h prior to transfection.
Following removal of growth medium, 200 ml of the complexes in OptiMEM con-
taining 50 or 100 nM siRNA were added to the cells in replicates of six. Plates were
centrifuged at 1500 rpm for 5 min (400  g) and incubated for 4 h at 37 C, then
mediumwas replaced by the full growthmedium and incubated for a further 24 h. In
transfections where serumwas present complexes made in OptiMEMwere added to
different amounts of complete media in order to obtain 5% and 10% serum-
containing media. L2K was used as a positive control for siRNA transfections and
the transfection procedures were performed in accordance with the manufacturer's
instructions, formulated at aweight ratio of 4 (L2K): 1 (siRNA). Luciferase expression
was then measured in cell extracts with a luciferase assay (Promega, Southampton,
UK) in a FLUOstar Optima luminometer (BMG Labtech, Aylesbury, UK). The amount
of protein present in each cell lysate was determined with the Bio-Rad protein assay
reagent (Bio-Rad Laboratories, Hemel Hempstead, UK) in a FLUOstar Optima
luminometer. Luciferase activity was expressed as relative light units per milligram
of protein (RLU/mg). Each measurement was performed in groups of six and the
mean determined. The GAPDH gene knockdown assays were conducted 48 h
following transfection of Neuro-2A and 1HAEo-cells with RTNs containing Silencer
GAPDH siRNA or Silencer Negative Control #1 according to the manufacturer's in-
structions of the KDalert GAPDH assay kit (Applied Biosystems, Warrington, UK).
Experiments were repeated three times.
2.5. Particle size and charge measurements
Nanocomplexes were prepared as above and diluted with distilled water to a
ﬁnal volume of 1 ml and a concentration of 5 mg/ml siRNA. They were then analyzed
for size and charge (z potential) using a Malvern Nano ZS (Malvern, UK). The data
were then processed by software provided by the manufacturer, DTS version 5.03.
All formulations had a polydispersity index (PDI) of less than 0.3. The values for each
formulation are the means of three measurements and the experiments were
repeated three times.
2.6. Turbidity assay
The absorbance of complexes in triplicates in the absence and presence of
different serum concentrations (0e50% v/v) was measured at 500 nm on a FLUOstar
Optima spectrophotometer as described previously with a corresponding amount of
serum alone as a reference [23].
2.7. PicoGreen ﬂuorescence quenching experiments
Brieﬂy, 0.2 mg siRNA was mixed with PicoGreen reagent (1:150) (Invitrogen,
Paisley, UK) at room temperature in TE buffer and the siRNA/PicoGreen mixture was
then formulated into nanocomplexes with anionic liposome and cationic peptide
into nanocomplexes as described above. Fluorescence was analyzed using a ﬂuo-
rescence plate reader, FLUOstar Optima (BMG Labtech, Aylesbury, UK). Heparin
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previously [21] and repeated three times.
2.8. Transmission electron microscopy (TEM)
For the electron microscopy investigations, the anionic nanoparticles prepared
as described above were applied onto a 300-mesh copper grid coated with a For-
mvar/carbon support ﬁlm (Agar Scientiﬁc, Stansted, UK) and processed as described
previously [23].
2.9. Scanning electron microscopy (SEM)
Samples in 8% trehalose (SigmaeAldrich, Poole, UK) were ﬁrst freeze-dried and
then adhered onto a SEM stub (Agar Scientiﬁc) using double-sided sticky carbon
discs (Agar Scientiﬁc, Stansted, UK) and the excess sample was blown off with
compressed air. Then the prepared stubwas given a 10 nm gold coating in a Quorum
Q150T Sputter Coater (Quorum Technologies, Lewes, UK) prior to viewing. Digital
images were captured under a FEI Quanta 200F SEM (FEI Company, Eindhoven,
Netherlands).
2.10. Cell proliferation assay
Cell viability of Neuro-2A cells was assessed in 96-well plates in replicates of six
using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega,
Southampton, UK), as described previously [23].
2.11. Confocal microscopy
1.5  105 Neuro-2A cells were seeded onto poly-L-lysine coated slides (SLS,
Dublin, Ireland). The following day they were transfected with Cy3-labelled GAPDH
siRNA (100 pmol; ﬁnal concentration of siRNA ¼ 200 nM; Applied Biosystems,
Warrington, UK) complexed with L2K at a 4:1 weight ratio or PRL formulations in
triplicates. After 4 h incubation the slides were processed and visualized on a Carl
Zeiss LSM710 laser scanning microscope system (Jena, Germany) at a magniﬁcation
of x400 as described previously [21]. For the GAPDH silencing experiments the
Neuro-2A cells were transfected in triplicates as above with GAPDH siRNA or irrel-
evant control siRNA complexed with different nanocomplexes. After 48 h incubation
the slides were processed and visualized on a Carl Zeiss LSM710 laser scanning
microscope system at a magniﬁcation of x400 as described previously [21].
2.12. In vivo CED procedures
All in vivo studies were performed in accordance with University of Bristol an-
imal care policies and with the authority of appropriate UK Home Ofﬁce licences.
Adult male Wistar rats (Charles River, Margate, UK, 225e275g) were used for CED as
described previously [23]. A total volume of 5 ml (5.6 mg of siRNA or 0.02 mg/kg) of
anionic PEGylated nanoparticles in 5% dextrose was delivered to the striatum at an
infusion rate of 2.5 ml/min. Rats were euthanized, and striata were placed in RNA-
later (Invitrogen, Paisley, UK).
2.13. qRT-PCR
Rat brains were collected in RNAlater (Invitrogen, Paisley, UK) and total RNAwas
extracted from rat brain using the RNeasy kit according to the manufacturer's in-
structions (Qiagen, Crawley, UK). RNA was checked for integrity using the Agilent
2100 Bioanalyzer (Wokingham, UK). All RNA samples had an RNA integrity number
(RIN) of more than 8 indicating high quality RNA. Prior to reverse transcription, each
RNA sample underwent DNase treatment (Invitrogen, Paisley, UK) to eliminate any
potential genomic DNA contamination. First-strand DNAwas synthesized from 1 mg
of DNase-treated RNA, using random hexamers and Superscript II reverse tran-
scriptase (Invitrogen, Paisley, UK) in a 1 h reaction at 37 C. Rat BACE1 and rat beta-
actinwere then quantiﬁed using Taqman primers and probes (Rn00569988_m1 and
Rn00667869_m1, respectively; Life Technologies, Paisley, UK) and an ABI PRISM
7000 Sequence Detection System (Applied Biosystems, Warrington, UK). The qRT-
PCR assay conditions were: stage 1, 50 C for 2 min; stage 2, 95 C for 10 min;
stage 3, 95 C for 15 s, then 60 C for 1 min; repeated 40 times.
2.14. Western blot
Total protein was extracted from rat brain striatum in lysis buffer consisting of
75 mM TriseHCl, 1% SDS and cocktail of protease inhibitor (Roche, West Sussex, UK)
using Precellys Homogeniser (Stretton Scientiﬁc, Stretton, Derbyshire, UK). Protein
was quantiﬁed by BCA protein assay kit (Thermo Fisher Scientiﬁc, Northumberland,
UK). Forty micrograms of protein was loaded and separated using NuPAGE Pre-cast
gels (10% Bis-Tris, Invitrogen, Paisley, UK) and then transferred electrophoretically to
PVDF membrane (Invitrogen, Paisley, UK). The membrane was blocked in 10%
skimmed milk in phosphate buffered saline buffer with 0.5% Tween-20 (PBS-T) at
4 C overnight and then probed with the primary antibodies at room temperature
for 1 h. After washing in PBS-T, membranes were incubated with HRP-conjugated
anti-mouse or anti-rabbit IgG (Stratech Scientiﬁc, Suffolk, UK; 1:50,000) for 1 h at
room temperature. Membranes were then rinsed in PBS-T thoroughly at room
temperature before visualized by enhanced chemiluminescence detection kit (Bio-
Rad, Hemel Hempstead, UK). The primary antibodies used in this study includerabbit anti-BACE1 polyclonal antibody (EE-17, 1:1000; SigmaeAldrich, Poole, UK)
andmouse anti b-tubulin monoclonal antibody (1:5000; SigmaeAldrich, Poole, UK).
Semi-quantiﬁcation of the bands was performed by densitometry using the ImageJ
software.
2.15. 5’ rapid ampliﬁcation of the 50 cDNA ends-PCR (5’RACE-PCR)
To conﬁrm the BACE1 mRNA cleavage, following RNAi-mediated gene silencing
with BACE1 siRNA, 5’-RACE PCR was performed following the manufacturer's in-
structions (GeneRacer™ Kit, Invitrogen) with some modiﬁcations. Brieﬂy, total RNA
from each sample was ligated to the GeneRacer RNA oligo linker without prior
treatment. After Phenol/Chloroform precipitation, ﬁrst-strand cDNA was reverse
transcribed using the superscript™ III RT and a Gene-Speciﬁc Reverse Primer
(Supplementary Table S2). 1 mL cDNAwas ampliﬁed with GeneRacer™ 5' Primer and
the gene speciﬁc reverse primer (Supplementary Table S2) as follows; 1 cycle of
95 C for 2 min, then 15 touch-down cycles (repeating 3 cycles of 95 C for 30 s,
annealing from 67.5 C to 61.5 C with an increment of1.5 C for 30 s, and 72 C for
20 s), and 10 cycles of 95 C for 30 s, 60 C for 30 s, 72 C for 20 s, then 1 cycle of 72 C
for 10 min. From this product, 5 mL were used for nested PCR with a GeneRacer™ 5'
Nested Primer and a gene-speciﬁc reverse nested primer (Supplementary Table S2)
as follows; 1 cycle of 95 C for 2 min, then 15 touch-down cycles (repeating 3 cycles
of 95 C for 30 s, annealing from 62.5 C to 56.5 C with an increment of 1.5 C for
30 s, 72 C for 20 s), and 10 cycles of 95 C for 30 s, 60 C for 20 s, 72 C for 20 s, and
then 1 cycle of 72 C for 10min. 5 ml of the nested PCR product was then re-ampliﬁed
with an identical protocol of nested 5'-RACE PCR as described above. All PCR
products were puriﬁed with MineElute® PCR Puriﬁcation Kit (Qiagen) following the
manufacturer's instructions.
2.16. Statistical analysis
Data presented in this study are expressed as the mean ± standard deviation of
measurements performed in triplicates or replicates of six. They were then analyzed
using a two-tailed, unpaired Student t-test or one way ANOVA and Bonferroni post-
hoc analysis where applicable. Probability values p < 0.05 were marked with *,
p < 0.01 were marked with ** and p < 0.001 were marked with ***.
3. Results
3.1. Development and biophysical characterization of anionic
nanoparticles
LRP (Method 1) or PRL (Method 2) nanocomplexes were
formulated at anionic liposome:siRNA (L:R) molar charge ratios
from 5:1 to 1:1. LRP and PRL nanocomplexes were both strongly
anionic when the L:R molar charge ratio was 3:1 or greater with no
signiﬁcant size or charge differences (Fig. 1S-A and S-B). PicoGreen
ﬂuorescence assays (Fig. 1S-C) showed that PRL formulations
quenched approximately 50% more ﬂuorescence than LRP formu-
lations at all the ratios that produced anionic nanocomplexes
(L:R ratios of 5:3, 4:3 and 3:3). Therefore, based on the efﬁciency
of packaging and on our recent study where PDL nanocomplexes
resulted in better DNA transfection efﬁciencies [23], the PRL method
of mixing was used thereafter for all anionic nanocomplexes.
Anionic PEGylated nanocomplexes were then prepared with
PEG2000 lipids incorporated at a 5% molar ratio in liposomes based
on previous studies of extended circulation times and our own
study [23,26]. Two different PEG lipids were used, DPPE-PEG2000
in PRLAP1 and DOPE-PEG2000 in PRLAP2. Anionic nanocomplex
formulations were prepared at molar charge ratios of 5:3:1 and
4:3:1 and the zeta potentials of the PEGylated nanocomplexes at
both ratios were shown to be anionic (23 to 33 mV) with no
charge differences between them (Fig. 1A). PRLAP2 formulations
were bigger than both PRLAP1 and non-PEGylated PRLA (Fig. 1A)
while the charges of both PEGylated nanocomplexes were less
anionic than non-PEGylated nanocomplexes (e.g. 25 mV for
PRLAP1 vs 40 mV for PRLA at 4:3:1M molar charge ratio).
PicoGreen ﬂuorescence quenching studies were performed to
evaluate the effectiveness of packaging of siRNA within nano-
complexes in the presence or absence of 50% serum (Fig. 1B). The
cationic LPR formulation provided the best packaging (>95%) but in
the presence of serum 7.8-fold less siRNA was quenched. This
contrasts to the anionic formulations where 80e91% packaging was
Fig. 1. Development of anionic nanoparticles and biophysical characterization. A) Anionic non-PEGylated PRLA and PEGylated PRLAP1 and PRLAP2 nanoparticles were prepared at
different molar charge ratios and their size and charge was measured by dynamic light scattering. B) Relative ﬂuorescence unit (RFU) of the siRNA complexes as a percentage of
signal from free siRNA in ﬂuorescence quenching experiments in the presence or absence of 50% serum was measured for anionic nanoparticles that were made at different molar
charge ratios and for cationic LPR nanoparticles. C) The effect of 50% serum concentration on the relative turbidity of cationic and anionic nanocomplexes over a 30 min incubation
period. Cationic LPR nanocomplexes were made at 1:4:1 weight ratio, whereas the anionic nanocomplexes (PRLA, PRLAP1 and PRLAP2) were all made at 4:3:1molar charge ratio. D)
The dissociation properties of anionic PEGylated PRLAP1 and PRLAP2 and non-PEGylated PRLA nanocomplexes at 4:3:1 M charge ratio were investigated. PicoGreen ﬂuorescence of
complexes, after incubation with heparin (0e2 U/mL), was expressed as a percentage of RFU relative to free siRNA.
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the quenching was only reduced by 1.2e2-fold.
We then compared the different nanocomplexes for their sta-
bility in 50%mouse serum by assessing aggregationwith a turbidity
assay. The turbidity of both, PEGylated and non-PEGylated, anionic
nanocomplexes was less than half that of the cationic LPR formu-
lation, with PRLA showing slightly more turbidity than the PEGy-
lated anionic nanoparticles (Fig. 1C). The ability of anionic
nanocomplexes to package siRNA efﬁciently and to dissociate
following heparin challenge in order to release intact siRNA was
then assessed. PicoGreen-labelled siRNA was formulated into
anionic, PEGylated and non-PEGylated nanocomplexes at 4:3:1
molar charge ratios. Packaging was inferred from quenching of
ﬂuorescence compared to free siRNA as 100%. Non-PEGylated PRLA
at 95% quenching, packaged the siRNA better than PEGylated
PRLAP1 and PRLAP2 that both quenched siRNA ﬂuorescence by
approximately 85% (Fig. 1D). In addition, PRLA was the least sensi-
tive formulation to heparin as it achieved 50% dissociation at 0.21
U/mL heparin compared to PRLAP1 and PRLAP2 that both required
0.13 U/mL heparin. All formulations achieved 100% dissociation
following heparin challenge at higher concentrations (0.5 U/mL for
PRLA and 1.0 U/mL for both the PRLAP1 and PRLAP2).Anionic PRL nanoparticle formulations were further character-
ized by negative staining transmission electron microscopy (TEM)
to determine shape and morphology. Most nanocomplexes were
spheres but with some rods, while PRLAP2 also showed some
pleiomorphic structures (Fig. 2). The majority of the spherical
particles for each formulation were in the range determined by
particle size analysis with no obvious differences between formu-
lations. SEM showed that anionic nanoparticles were spherical and
immobilized in matrices of trehalose.
3.2. Enhanced targeted silencing and viability of cells transfected
with anionic PRLs
PEGylated (PRLAP1 and PRLAP2) and non-PEGylated (PRLA) for-
mulations at 4:3:1 molar charge ratios were compared for silencing
of luciferase in transfections of Neuro-2A-Luc cells (Fig. 3A). PRLAP1
was signiﬁcantly better by approximately 2.1efold and 1.8-fold
(p < 0.01 in both cases), than PRLAP2 and PRLA at 100 nM, respec-
tively and was only inferior to L2K at 50 nM (p < 0.05). The same
formulations were compared for silencing of GAPDH enzymatic
activity in 1HAEo-cells (Fig. 3B). Again PRLAP1 was signiﬁcantly
better by more than 2efold (p < 0.001 in both cases), than PRLAP2
Fig. 2. Electron microscopy of nanocomplexes. Negative staining transmission electron microscopy was used to visualize A) PRLA, B) PRLAP1, and C) PRLAP2 nanoparticles. Scale
bar ¼ 500 nm. D) Scanning electron microscopy was used to visualize PRLAP1 nanoparticles. Scale bar ¼ 4 mM.
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compared to L2K at 50 nM and 100 nM. In addition, when we
compared PRLAP1 formulations with targeting peptide Y or target-
ing peptide ME27 to non-targeting nanocomplexes, we achieved
luciferase silencing in Neuro-2A-Luc cells only with the targeted
nanoparticles (Fig. 2S).
We then assessed the ability of our anionic formulations to
achieve gene silencing in the presence of serum in transfections of
Neuro-2A-Luc cells. At both 10% (Fig. 3C) and 5% serum (Fig. 3D)
PRLAP1 resulted in 60% silencing, which was signiﬁcantly better
than either PRLAP2 (p < 0.05) or PRLA (p < 0.001 and p < 0.01 for 10%
and 5% serum, respectively). L2K resulted in more than 85%
silencing at both 5% and 10% serum, which was signiﬁcantly better
than PRLAP1 only at 10% serum (p < 0.01).
Anionic PRLA, PRLAP1 and PRLAP2 formulations were also
compared for cytotoxicity using two different siRNA concentra-
tions. MTS toxicity assays of transfected Neuro-2A cells (Fig. 3E)
showed that all three anionic formulations resulted in minimal
cytotoxicity with no differences between them.
3.3. Internalization of the siRNA complexes and silencing effect
Cellular uptake and distribution of siRNA delivered by anionic
nanocomplexes was studied in Neuro-2A cells transfected for 4 h
with formulations containing Cy3-labelled GAPDH siRNA. The cells
were stained with phalloidin for the cytoplasm and DAPI for the
nucleus, then assessed by confocal microscopy (Fig. 3S). Fluorescent
anionic PEGylated and non-PEGylated nanoparticles appeared in-
side the cytoplasm at 4 h with no ﬂuorescent siRNA observed in the
nucleus. These data are in agreement with our previous studieswhere we had shown intracellular detection of cationic nano-
complexes at 4 h [19,21].
In silencing experiments, Neuro-2A cells were transfected with
GAPDH siRNA and irrelevant control siRNA and analyzed by
confocal microscopy with an anti-GAPDH antibody (Fig. 4).
Silencing of GAPDH expression in Neuro-2A cells was evident
following transfection with L2K, PRLA, and PRLAP2 but was even
more pronouncedwith PRLAP1 nanocomplexes, therefore providing
further evidence for the silencing potency of the anionic PEGylated
formulations.
3.4. In vivo administration by CED of anionic PRLs demonstrated
silencing of BACE1
We then evaluated the in vivo knockdown of BACE1. PRLAP1
nanoparticles incorporating either BACE1 siRNA or irrelevant con-
trol siRNA were administered by CED into rat striata and BACE1
expression was examined 48 h later. A signiﬁcant reduction
(approximately 60%) in BACE1 mRNA was observed (Fig. 5A) be-
tween the BACE1-treated group and the control groups (p < 0.01
compared to the irrelevant control group and p < 0.001 compared
to the untreated control group). Western blotting analysis revealed
that BACE1 protein levels were also suppressed by ~30% compared
to both controls (Fig. 5B). 50 RACE-PCR analysis (Fig. 5C) detected
the predicted 240 bp cleavage product of mRNA only in samples
from BACE1 siRNA-treated rat brains and not in those receiving
irrelevant siRNA control or in untreated rats. Thus, the reduction in
BACE1 expression demonstrated by mRNA quantiﬁcation, mRNA
cleavage analysis and the protein quantiﬁcation support an RNAi-
mediated mechanism of gene silencing.
Fig. 3. SiRNA knockdown in the presence or absence of serum and cell viability. A) PRLA, PRLAP1, PRLAP2 at 4:3:1 molar charge ratio using siRNA targeting luciferase in Neuro-2A-Luc
cells at two concentrations, 50 and 100 nM. 24 h later luciferase assays were performed. B) PRLA, PRLAP1, PRLAP2 at 4:3:1 molar charge ratio using siRNA targeting GAPDH in 1HAEo-
cells at two concentrations, 50 and 100 nM. 48 h later GAPDH assays were performed. C) PRLA, PRLAP1, PRLAP2 at 4:3:1 molar charge ratio using siRNA targeting luciferase in Neuro-
2A-Luc cells at 100 nM were investigated for their ability to perform silencing in the presence of 10% serum. 24 h later luciferase assays were performed. D) PRLA, PRLAP1, PRLAP2 at
4:3:1 molar charge ratio using siRNA targeting luciferase in Neuro-2A-Luc cells at 100 nM were investigated for their ability to perform silencing in the presence of 5% serum. 24 h
later luciferase assays were performed. All results shown (AeD) have been normalized with values for the same formulations using irrelevant control siRNAwhich were set at 100%.
L2K/siRNA nanocomplexes were used as a positive control in all in vitro silencing experiments. E) Viability of Neuro-2A-Luc cells following transfection for 24 h with PRLA, PRLAP1,
PRLAP2 at 50 and 100 nM (all siRNAs were targeting luciferase). Viability values were normalized to the untransfected control cells. All transfections were performed in groups of six
and mean values were calculated. Asterisks indicate comparisons of speciﬁc formulations with statistical signiﬁcance (*, p < 0.05 and ***, p < 0.001).
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Anionic nanocomplexes are attracting increasing scientiﬁc
attention as an approach to circumvent problems associated withthe in vivo use of cationic nanoparticles such as poor tissue speci-
ﬁcity, toxicity and rapid clearance from the circulation. Anionic
formulations for DNA delivery have shown evidence of improved
biodistribution, efﬁcacy and reduced toxicity compared to cationic
Fig. 4. SiRNA silencing of GAPDH gene expression. GAPDH siRNA and irrelevant control siRNA transfected into Neuro-2A cells, and analyzed by ﬂuorescence microscopy with an
anti-GAPDH antibody. Blue: DAPI for the nucleus Green: ﬂuorescein-labelled antibody to GAPDH. SiRNA silencing of GAPDH expression in Neuro-2A cells is demonstrated following
transfection with L2K, PRLA, PRLAP1 and PRLAP2 complexes with siRNA targeting GAPDH. UNTR ¼ untreated cells. Scale bar ¼ 20 mm.
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geting [26-29]. Anionic formulations have also been used for siRNA
silencing with similarly promising results in vitro [9,10,30] and
in vivo [14] including tumour targeting [11-13,15]. Hence, there is a
need for additional research to optimize the design, formulation
and applications of anionic nanocomplexes.We are developing anionic, targeted formulations comprising
a mixture of peptide ligands and anionic, PEGylated liposomes
that self-assemble into anionic nanocomplexes with DNA or
siRNA at optimized ratios of components and order of mixing.
Our ﬁrst such formulation with a DNA cargo displayed far su-
perior distribution in rat brain than homologous cationic
Fig. 5. In vivo silencing of BACE1 following CED administration of PEGylated nanoparticles into rat striatum. A) Anionic PEGylated PRLAP1 nanoparticles with BACE1 siRNA or
irrelevant control siRNA were administered by CED in the striatum of rats and 48 h post administration tissues were removed for qRT-PCR analysis of siRNA-induced silencing of
BACE1 gene. Values are the means of 6 animals ± standard deviation (n ¼ 5 for the Untreated control animals) with one way ANOVA and Bonferroni post-hoc analysis performed to
calculate signiﬁcant differences (*, p < 0.05; ***, p < 0.001). B) Western blot analysis of BACE1 protein in rat striatum following CED administration of anionic PEGylated PRLAP1 with
BACE1 siRNA or irrelevant control siRNA, 48 h post-administration. Silencing was calculated with densitometric analysis using tubulin as loading control. C) SiRNA speciﬁc cleavage
following CED administration of PRLAP1 nanoparticles. A schematic diagram of the 5' RACE-PCR method for BACE1 mRNA cleavage is provided. Cleaved BACE1 mRNA resulted in the
242bp nested PCR products which are indicative of siRNA-speciﬁc cleavage. The actual gel image of the 50 RACE-PCR products is shown. RNA was extracted from rat brains of mice
which were either treated with BACE1 siRNA or irrelevant control siRNA encapsulated in PRLAP1 nanoparticles or from brains of untreated control rats and was then subjected to 50
RACE-PCR. M: 100 bp DNA ladder; Lane 1: Untreated rat; Lanes 2e3: irrelevant control siRNA treated rats; Lanes 4e5: BACE1 siRNA treated rats.
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transfection efﬁciencies in vitro [23]. Here we have focused on
developing anionic nanoparticles for siRNA delivery and inves-
tigated the effects of PEGylated formulations. We relate the
biophysical properties of these nanocomplexes to their silencing
efﬁciencies in vitro and we report the effects of administration
of these siRNA anionic nanocomplexes in vivo, in rat brain. We
used a targeting peptide in the formulation that targets multiple
cells with high transfection efﬁciency and was shown previ-
ously to be effective in the brain for targeted DNA delivery
[19,21,23].We ﬁrst optimized methods of mixing and molar charge ratios,
then structural and functional studies were performed to compare
the PEGylated formulations with non-PEGylated anionic and
cationic formulations. The anionic PEGylated nanoparticles of
~110 nm were similar (PRLAP1) or slightly larger (PRLAP2) in
diameter than non-PEGylated anionic formulations (PRLA),
whereas their charge was less anionic due probably to PEG
shielding [31]. TEM analysis of anionic nanoparticles showed that
there were no major differences in morphology between the
different PEGylated and non-PEGylated anionic formulations or
cationic LPR nanocomplexes reported previously [21].
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in cationic LPR possibly because the two cationic moieties (lipo-
some and peptide) in LPR exert more force to siRNA than the one
cationic moiety (peptide) in the anionic formulations. In addition,
PEGylation in PRLAP1 and PRLAP2 resulted in more efﬁcient pack-
aging of siRNA than the non-PEGylated PRLA. We then tested the
nanoparticle stability in turbidity assays using 50% mouse serum to
better reﬂect in vivo conditions [32]. PEGylated and non-PEGylated
PRLA formulations were far more stable in serum than cationic
nanocomplexes, which aggregated due to their interactions with
anionic serum proteins as reported previously for cationic lipo-
somes [33]. In addition, ﬂuorescently labelled siRNA in cationic
nanocomplexes was quenched 8-fold less in serum than in non-
serum conditions, whereas the quenching of anionic nano-
particles was reduced less than two fold in serum compared to
serum-free conditions. Aggregation of cationic nanocomplexes
leads to reduced bioavailability and binding to cells, increased
toxicity and clearance in vivo by the RES [32] and so the improved
behaviour of anionic nanocomplexes in serum suggests that their
bioavailability and activity in vivo should be enhanced.
We next assessed the stability of nanocomplexes to anionic
challenge as an indication of their potential to dissociate and
release siRNA in the cytoplasm. While extracellular stability is an
essential requirement for an effective siRNA delivery formulation,
effective transfection and silencing is also inﬂuenced by the ease of
release of the siRNA within the cell following internalization [21].
PEGylated anionic nanocomplexes dissociated more readily than
non-PEGylated formulations which required approximately 60%
more heparin to achieve 50% dissociation. The different sensitivities
of PEGylated and non-PEGylated anionic nanocomplexes to hepa-
rin, may be explained by the greater anionic charge of the latter.
We then compared the silencing efﬁciencies of the anionic for-
mulations using two different cell lines, Neuro-2A-Luc and 1HAEo-
in 5% and 10% serum or serum-free conditions. PRLAP1emediated
silencing of 60e80% that was signiﬁcantly better than PRLAP2 and
non-PEGylated PRLA for both luciferase and the endogenous
GAPDH gene in both, serum-containing or serum-free conditions
PRLAP1 and similar to levels achieved with L2K. Both cationic and
anionic formulations prepared with two different targeting pep-
tides, peptide Y and peptide ME27 [18,19,23,34], showed the ne-
cessity for the peptide targeting ligand where formulations with
control, non-targeting peptides were inactive. Furthermore,
confocal studies of silencing endogenous GAPDH also demon-
strated the potential of the PEGylated anionic nanocomplexes for
silencing. Toxicity assays showed that both PEGylated and non-
PEGylated anionic formulations were not cytotoxic as also re-
ported previously with other anionic formulations [14,23,35,36].
In relating differences in silencing efﬁciency to biophysical
properties, PRLA possessed the highest anionic charge and was the
least efﬁcient formulation for siRNA release and serum aggregation.
The high anionic surface charge would reduce cell surface in-
teractions and endocytosis and this, combinedwith its worse siRNA
release kinetics helps to explain the poor silencing efﬁciency
compared to PRLAP1 which displayed better silencing efﬁciency
associated with improved dynamic properties of the nano-
complexes in that it packaged and released siRNA effectively,
aggregated less and had a lower anionic surface charge than the
non-PEGylated formulation. Of the two PEGylated formulations,
PRLAP2 was slightly bigger than PRLAP1 but otherwise presented
with similar biophysical properties of charge and morphology and
same properties for packaging, dissociation and serum aggregation.
Therefore, the difference in silencing between PRLAP1 and PRLAP2
can only be explained by the fact that the PEGylated lipid moiety in
PRLAP1 is a C16 saturated acyl chain while in PRLAP2 it is a C18
unsaturated acyl chain. The effectiveness of lipids with shorter alkyltails in siRNA silencing might be explained by the fact that the
shorter length of the alkyl chain is associated with greater alkyl tail
ﬂexibility and a lower phase transition temperature from crystal-
line to ﬂuid phases of the bilayer in vesicles [37] and so may help to
confer the greater gene silencing efﬁciency by promoting endo-
somal release of the siRNA.
We then performed in vivo experiments wherewe administered
by CED nanoparticles for BACE1 silencing. BACE1 is the rate-limiting
enzyme in the production of Ab peptides which are landmarks in
AD pathophysiology [24]. Both the expression and enzymatic ac-
tivity of BACE1 are increased in brains of AD patients [38], whereas
in BACE1 knockout mice there is no generation of Ab peptides [39].
BACE1 is ubiquitously expressed in the brain, including high levels
of expression in the striatum, with higher expression levels
observed in neurons compared to other cell types [38]. BACE1 is
therefore amain therapeutic target for AD. PRLAP1 resulted in about
a 60% reduction in BACE1 mRNA compared to the untreated group,
which was similar to a study using systemic injection and targeted
exosomes [40], and 30% protein silencing. The group treated with
the irrelevant control siRNA, a group not included in the exosome
study [40], resulted in about 30% mRNA knockdown but this was
unspeciﬁc as it did not show any protein silencing and importantly
the 5’RACE analysis clearly conﬁrmed that only PRLAP1-BACE1
siRNA containing nanoparticles silenced BACE1 through RNAi.
BACE1 is also expressed by other cell types at lower levels e.g. as-
trocytes and microglia [41] and all three cell types (neurons, as-
trocytes and microglia) are present in the striatum [42]. Injury that
may be caused by the implantation of the catheter during CED
either directly attract microglia or might activate astrocytes [43,44]
which in turn might mediate rapid microglial response through
signalling [45,46]. Therefore, more cell types are present and thus
the BACE1 levels might be changed. Non-speciﬁc silencingmight be
the result of this change in the cell population harvested and pro-
cessed for mRNA isolation. It was reported that, as long as BACE1
proteinwas even reduced partially, Ab levels may be decreased and
that lowering the Ab peptide generation by 20e30% is sufﬁcient to
retard the pathological development and defer the inception of
symptomatic AD [38,47]. Hence, it is not necessary to entirely
inhibit Ab peptide generation to treat AD. Therefore, based on the
present knowledge it is plausible that partial lowering of BACE1
expression at the levels achieved here may prove beneﬁcial to AD
sufferers. Further studies using multiple, repeated siRNA dosing
and investigating the duration of the silencing effect may achieve
higher levels of silencing for a sustained period. Ideally, nano-
particles would be administered through the bloodstream and by-
pass the blood-brain barrier by taking advantage of endogenous
receptors but this remains an obstinate challenge to the ﬁeld and
so, for now, CED provides an effective method of direct
administration.
5. Conclusions
In this study we describe an anionic modular PEGylated nano-
complex and demonstrated enhanced silencing efﬁciency of
different genes. The silencing efﬁciency of PRLAP1 was comparable
with that of the commercial transfection agent L2K, but without the
signiﬁcant cytotoxicity which is associated with the latter. Distri-
bution of nanoparticles in the brain, administered by direct delivery,
resulted in BACE-1 gene silencing demonstrating the potential to
advance the ﬁeld of siRNA therapeutics for several disorders.
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